A multivalent vaccine and single platform diagnostic for bacterial respiratory diseases of pigs
Lead Research Organisation:
London Sch of Hygiene & Tropic. Medicine
Department Name: Infectious and Tropical Diseases
Organisations
Publications
Faulds-Pain A
(2013)
Improved Bacterial Mutagenesis by High-Frequency Allele Exchange, Demonstrated in Clostridium difficile and Streptococcus suis
in Applied and Environmental Microbiology
Donkor ES
(2012)
Comparative phylogenomics of Streptococcus pneumoniae isolated from invasive disease and nasopharyngeal carriage from West Africans.
in BMC genomics
Howell KJ
(2014)
The use of genome wide association methods to investigate pathogenicity, population structure and serovar in Haemophilus parasuis.
in BMC genomics
Passmore IJ
(2019)
Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines.
in BMC veterinary research
Hau SJ
(2020)
Evaluation of the recombinant proteins RlpB and VacJ as a vaccine for protection against Glaesserella parasuis in pigs.
in BMC veterinary research
Baig A
(2015)
Whole genome investigation of a divergent clade of the pathogen Streptococcus suis.
in Frontiers in microbiology
Da Silva GC
(2022)
Identification of small RNAs associated with RNA chaperone Hfq reveals a new stress response regulator in Actinobacillus pleuropneumoniae.
in Frontiers in microbiology
Bossé JT
(2016)
ICEApl1, an Integrative Conjugative Element Related to ICEHin1056, Identified in the Pig Pathogen Actinobacillus pleuropneumoniae.
in Frontiers in microbiology
Bossé JT
(2017)
Whole Genome Sequencing for Surveillance of Antimicrobial Resistance in Actinobacillus pleuropneumoniae.
in Frontiers in microbiology
Majorova D
(2021)
Use of Precision-Cut Tissue Slices as a Translational Model to Study Host-Pathogen Interaction.
in Frontiers in veterinary science
Gibson AJ
(2021)
Probing Differences in Gene Essentiality Between the Human and Animal Adapted Lineages of the Mycobacterium tuberculosis Complex Using TnSeq.
in Frontiers in veterinary science
Bossé JT
(2016)
Complete Genome Sequence of MIDG2331, a Genetically Tractable Serovar 8 Clinical Isolate of Actinobacillus pleuropneumoniae.
in Genome announcements
Eberle KC
(2020)
Generation and Evaluation of a Glaesserella (Haemophilus) parasuis Capsular Mutant.
in Infection and immunity
Brockmeier SL
(2018)
Use of Proteins Identified through a Functional Genomic Screen To Develop a Protein Subunit Vaccine That Provides Significant Protection against Virulent Streptococcus suis in Pigs.
in Infection and immunity
Howell KJ
(2013)
Gene content and diversity of the loci encoding biosynthesis of capsular polysaccharides of the 15 serovar reference strains of Haemophilus parasuis.
in Journal of bacteriology
Bossé JT
(2014)
Multiplex PCR assay for unequivocal differentiation of Actinobacillus pleuropneumoniae serovars 1 to 3, 5 to 8, 10, and 12.
in Journal of clinical microbiology
Wileman TM
(2019)
Pathotyping the Zoonotic Pathogen Streptococcus suis: Novel Genetic Markers To Differentiate Invasive Disease-Associated Isolates from Non-Disease-Associated Isolates from England and Wales.
in Journal of clinical microbiology
Howell KJ
(2017)
"Pathotyping" Multiplex PCR Assay for Haemophilus parasuis: a Tool for Prediction of Virulence.
in Journal of clinical microbiology
Howell KJ
(2015)
Development of a Multiplex PCR Assay for Rapid Molecular Serotyping of Haemophilus parasuis.
in Journal of clinical microbiology
Pereira MF
(2015)
Galleria mellonella is an effective model to study Actinobacillus pleuropneumoniae infection.
in Microbiology (Reading, England)
Faulds-Pain A
(2019)
The Streptococcos suis sortases SrtB and SrtF are essential for disease in pigs.
in Microbiology (Reading, England)
Bossé JT
(2020)
Draft Genome Sequences of the Type Strains of Actinobacillus indolicus (46K2C) and Actinobacillus porcinus (NM319), Two NAD-Dependent Bacterial Species Found in the Respiratory Tract of Pigs.
in Microbiology resource announcements
Weinert LA
(2019)
Publisher Correction: Genomic signatures of human and animal disease in the zoonotic pathogen Streptococcus suis.
in Nature communications
| Description | Through this research program we were able to 1) improve the diagnosis, 2) understand the epidemiology and 3) produce improved vaccine candidates against three major pig pathognes Actinobacillus pleuropneumoniae, Streptpcoccos suis and Haemophilus parasuis |
| Exploitation Route | Improved diagositcs, antimicrobials and vaccines |
| Sectors | Agriculture Food and Drink Pharmaceuticals and Medical Biotechnology |
| Description | Bovine Tuberculosis |
| Amount | £11,051,222 (GBP) |
| Funding ID | BB/N004590/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 09/2019 |
| Description | DSTL Glycoconjugate vaccine design |
| Amount | £450,000 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2011 |
| End | 09/2014 |
| Description | DSTL Glycoconjugate vaccine design for Coxiella |
| Amount | £600,000 (GBP) |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2012 |
| End | 08/2015 |
| Description | Developing and expanding the bacterial glycotoolbox for animal pathogens |
| Amount | £200,000 (GBP) |
| Funding ID | BB/M01925X/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 09/2017 |
| Description | Development and application of an Advanced Glycan Production Platform |
| Amount | £447,107 (GBP) |
| Funding ID | BB/W006146/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2022 |
| End | 01/2025 |
| Description | Development and testing of a Streptococcus suis glycoconjugate vaccine |
| Amount | £550,000 (GBP) |
| Organisation | Research Councils UK (RCUK) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2021 |
| Description | Development, production and testing of novel glycoconjugate pig vaccines |
| Amount | £600,000 (GBP) |
| Funding ID | BB/S004963/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 02/2021 |
| Description | GlycoCell |
| Amount | £12,300,000 (GBP) |
| Funding ID | BB/Y008472/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2024 |
| End | 02/2029 |
| Description | Glycoengineering of Veterinary Vaccines |
| Amount | £5,300,000 (GBP) |
| Funding ID | BB/N001591/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2021 |
| Title | Provision of bank of E coli glycoengineering strains |
| Description | Provision of bank of E coli glycoengineering strains that are available free from the Belgium Co-ordinated Collection of Microorganisms |
| Type Of Material | Biological samples |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | The bank of E coli glycoengineering strains that are available free from the Belgium Co-ordinated Collection of Microorganisms were the most requested strains from this major collection in 2023, and we were given an award. |
| URL | https://www.biodiversity.be/5177/#:~:text=BCCM%2FLMG%20is%20a%20bacterial,Contact%3A%20lmg%40UGent.b... |
| Description | Hilleman Labs |
| Organisation | MSD Wellcome Trust Hilleman Laboratories |
| Country | India |
| Sector | Charity/Non Profit |
| PI Contribution | Intellectual contribution and vaccine development and production. |
| Collaborator Contribution | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Merck MSD |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | Collaboration on vaccine development |
| Collaborator Contribution | Intellectual contribution and vaccine development and production |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Vabiotech vaccine production |
| Organisation | VabioTech |
| Country | Viet Nam |
| Sector | Public |
| PI Contribution | Intellectual contribution and vaccine development and production. |
| Collaborator Contribution | Intellectual contribution and vaccine development and production. |
| Impact | Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture |
| Start Year | 2020 |
| Description | Vaccine development for defence purposes |
| Organisation | Defence Science & Technology Laboratory (DSTL) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | New vaccine technology platform for making glycoconjugate vaccines against Burkholderia pseudomallei and Francisella tulerensis |
| Collaborator Contribution | Technology know how, specific animal testing facilities |
| Impact | Several vaccine candidates tested and some may go forward to vaccine trials |
| Title | Attenuated Streptococcus suis bacterial cells |
| Description | Novel low cost Streptococcal suis vaccine |
| IP Reference | GB1704101.2 |
| Protection | Patent granted |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | Improved pig vaccine |
| Company Name | ArcVax |
| Description | ArcVax develops animal vaccines using glycotechnology, designed to protect against diseases. |
| Year Established | 2016 |
| Impact | To rapidly develop low cost candidate glycoconjugate vaccines, eg multiprotective vaccines for poultry. |
| Description | Co-Director of Vaccine Centre |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | As Co-Director of LSHTM vaccines Centre have contributed to several vaccines related event for The General Public, Schools and Industry |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.lshtm.ac.uk/research/centres/vaccine-centre |
| Description | TV Broadcasts |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC Breakfast TV interview on vaccine design and antimicrobial resistance BBC one interview on Campylobacter in Food chain One Show BBC on antimicrobial resistance |
| Year(s) Of Engagement Activity | 2015 |